Group 1 - The core point of the news is that Beijing Baipusais Biotechnology Co., Ltd. has seen a stock price increase of 5.1%, reaching 57.66 CNY per share, with a total market capitalization of 9.678 billion CNY [1] - The company was established on July 22, 2010, and went public on October 18, 2021, focusing on providing key biological reagent products and technical services, with main revenue sources being recombinant proteins (82.27%), antibodies and other reagents (12.88%), technical services (3.04%), and others (1.80%) [1] Group 2 - The Hongta Hongtu Fund has a significant holding in Baipusais, with its Hongta Hongtu Medical Selected Stock Fund A (020331) being the largest shareholder, holding 10,000 shares, which constitutes 5.61% of the fund's net value [2] - The fund has seen a year-to-date return of 27.02% and a one-year return of 21.23%, ranking 1770 out of 4220 and 2155 out of 3857 in its category, respectively [2] Group 3 - The fund manager of Hongta Hongtu Medical Selected Stock Fund A is Cao Yang, who has been in the position for 2 years and 34 days, with the fund's total asset size at 12.7543 million CNY [3] - During his tenure, the best fund return was 27.6%, while the worst was -33.52% [3]
百普赛斯股价涨5.1%，红塔红土基金旗下1只基金重仓，持有1万股浮盈赚取2.8万元